Abstract 173P
Background
Breast cancer (BC) presents challenges in predicting disease progression despite advancements in treatment and monitoring. Circulating tumor cells (CTCs) were initially seen as promising for prognosis via liquid biopsy, but complexities in their investigation have emerged over the past 15 years. Variability in isolation methods and the absence of universal CTC markers hinder standardization and comparison of research findings. In the present study we focused on CD24 which shows potential as a prognostic marker of BC. This study aims to elucidate the prognostic significance of CD24+ circulating cells in peripheral blood of BC patients.
Methods
The study included 57 patients with invasive breast carcinoma of no special type (IC NST) T1-4N0-3M0-1. Circulating cell phenotypes assessment was carried out by flow cytometry (Novocyte 3000, ACEA Biosciences, USA) using monoclonal antibody cocktail.
Results
In our investigation we utilized epithelial markers EpCAM and cytokeratin 7/8 to assess CTCs, including both metastatic and non-metastatic BC patients. Surprisingly, these markers were insufficient in identifying CTC populations indicative of distant metastasis in BC. However, we made the intriguing discovery of CD45-CD24+ circulating cells lacking epithelial markers EpCAM and CK7/8 associated with distant metastasis. Increased level of CD45-EpCAM-CK7/8-CD24+N-cadherin- circulating cells were observed among patients with established metastases and those who developed metastatic lesions during subsequent monitoring. Furthermore, exceeding a threshold of 218.3 cells per milliliter of peripheral blood before treatment predicted a 12-fold increase in metastatic risk and a 3-fold reduction in DMFS over a 90-month period. The unveiled cell population could originate with equal probability from epithelial cells that have undergone EMT or from immature cells from bone marrow. However, it should be noted that these CCs do not align with any recognized stages of monocyte or neutrophil maturation.
Conclusions
The count of CD45-EpCAM-CK7/8-CD24+N-cadherin- CCs was associated with distant metastasis, as their numbers were elevated in peripheral blood of patients with metastases during the follow-up period.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Russian Science Foundation (grant #23-15-00135).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop
Presenter: Vincent de Jager
Session: Poster session 08
114P - Prevalence and landscape of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma
Presenter: Oscar Gerardo Arrieta Rodriguez
Session: Poster session 08
115P - Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
Presenter: Marie Morfouace
Session: Poster session 08
116P - Single-cell RNA sequencing reveals a subset of FSIP1 cancer cells and verified its value of prognosis in lung adenocarcinoma
Presenter: Xiaochen Zhang
Session: Poster session 08
Resources:
Abstract
117P - Methylome and transcriptome profiling of hepatoid adenocarcinoma of the stomach
Presenter: Shirong Zhang
Session: Poster session 08
Resources:
Abstract
118P - Comparative analysis of DNA and RNA-based NGS for detecting MET exon 14 skipping mutation in pan-solid tumor samples
Presenter: Ruijun Cai
Session: Poster session 08
119P - Predicting the pathogenicity of novel fusion genes and explaining reasons using a large language model: A focused assessment
Presenter: Katsuhiko Murakami
Session: Poster session 08
120P - A prospective comparative evaluation of automatic trial match tools in a molecular tumor board
Presenter: Lilia GUEGUEN
Session: Poster session 08